Quantcast

Rochester Medical Announces New Opportunity in the United Kingdom

September 21, 2009

STEWARTVILLE, Minn., Sept. 21 /PRNewswire-FirstCall/ — Rochester Medical Corporation (Nasdaq: ROCM) today announced that the Company’s FemSoft(R) Insert has been approved for inclusion in Part IX of the UK Drug Tariff as a prescription product which is reimbursable.

There are no other products listed in the Drug Tariff specifically for managing female stress urinary incontinence, and the Company believes that for many women this will be a very welcome addition that offers a discreet, non-surgical, odor-free, secure, and safe alternative to absorbents.

FemSoft(R) Inserts are particularly effective in situations where leakage occurs during certain physical activities such as exercise, coughing, laughing, or sneezing.

Hugh McLeod, General Manager of the U.K. business commented that this represents a significant opportunity for Rochester Medical and will enhance the Company’s position as the leading worldwide innovator and marketer of silicone continence care devices.

He noted that the FemSoft(R) Insert product line fits perfectly alongside Rochester Medical’s current portfolio of catheters for intermittent self-catheterization and will be marketed through the same customer base of Urology Nurse Specialists and Continence Nurse Specialists.

Commenting on the news, Anthony J. Conway Rochester Medical CEO and President said, “This is excellent news for women in the United Kingdom and also great news for Rochester Medical. We believe the FemSoft(R) Insert provides an elegant non-surgical, comfortable, and dry alternative to absorbents. Earlier this year we announced that U.S. Medicare has given preliminary reimbursement approval to the FemSoft Insert, and we expect final confirmation in the near future. In both the U.K. and U.S. we expect implementation of the reimbursement to begin in January 2010, and we are making sales and marketing preparations accordingly.”

About Rochester Medical

Rochester Medical is the world’s leading manufacturer of all-silicone catheters for urological and continence care applications. Our advanced line of latex-free products features male external catheters, intermittent catheters, Foley catheters and urethral inserts as well as latex-free accessories.

More information about Rochester Medical is available on its website at http://www.rocm.com.

Forward-Looking Statement

This press release contains “forward-looking statements” that are based on currently available information, operating plans and management’s expectations about future events and trends. They inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company’s products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company’s SEC reports and filings, including, without limitation, the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended September 30, 2008 and subsequent reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact: Anthony J. Conway
    President and Chief Executive Officer
    Rochester Medical Corporation
    Phone: (507) 533-9600

SOURCE Rochester Medical Corporation


Source: newswire



comments powered by Disqus